Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OncoMed Earns $72.5M Celgene Milestones | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

OncoMed Earns $72.5M Celgene Milestones

Achieves safety data and clinical candidate designation

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OncoMed Pharmaceuticals achieved two milestones from Celgene Corp. totaling $70 million based on analysis of Phase Ib and interim Phase II clinical trial safety data associated with the demcizumab (anti-DLL4, OMP-21M18) program. 
 
The data from the pancreatic, non-small cell lung and ovarian cancer clinical trials showed no demcizumab-related Grade 3 or higher cardio-pulmonary toxicities among 155 patients treated.  Of those, 68 patients have received at least two cycles of demcizumab at the Phase II dose or higher and have been followed for at least 100 days. 
 
OncoMed also earned a $2.5 million milestone for clinical candidate designation of an undisclosed preclinical immuno-oncology program.  This is OncoMed’s second immuno-oncology program to reach clinical candidate designation, and both programs are advancing in IND-enabling studies. 
 
“The achievement of the demcizumab $70 million safety milestone is based on extensive Phase Ib and blinded Phase II data, and positions OncoMed to rapidly enroll its Phase II randomized YOSEMITE and DENALI clinical trials, as well as the Phase Ib demcizumab plus pembrolizumab (anti-PD1) trial, and also to explore the potential of demcizumab in ovarian cancer,” said Paul J. Hastings, OncoMed’s chairman and chief executive officer. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics